These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1273 related articles for article (PubMed ID: 30603725)

  • 1. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
    Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
    Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges.
    Liu X; Qin S
    Oncologist; 2019 Feb; 24(Suppl 1):S3-S10. PubMed ID: 30819826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond.
    Feng MY; Chan LL; Chan SL
    Curr Oncol; 2022 Aug; 29(8):5489-5507. PubMed ID: 36005172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint inhibitors: literature review of new treatments for hepatocellular carcinoma.
    Biglow L; Ashraf S; Alsharedi M
    Stem Cell Investig; 2021; 8():22. PubMed ID: 34917675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?
    Mahipal A; Tella SH; Kommalapati A; Lim A; Kim R
    Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31366113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Longo V; Brunetti O; Gnoni A; Licchetta A; Delcuratolo S; Memeo R; Solimando AG; Argentiero A
    Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31627433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.
    Shrestha R; Prithviraj P; Bridle KR; Crawford DHG; Jayachandran A
    J Clin Med; 2021 Apr; 10(9):. PubMed ID: 33925488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
    Ouyang T; Kan X; Zheng C
    Front Oncol; 2022; 12():898964. PubMed ID: 35785169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma.
    Nishida N; Kudo M
    Hepatol Res; 2018 Jul; 48(8):622-634. PubMed ID: 29734514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.
    Cheng H; Sun G; Chen H; Li Y; Han Z; Li Y; Zhang P; Yang L; Li Y
    Am J Cancer Res; 2019; 9(8):1536-1545. PubMed ID: 31497341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in the study of programmed cell death protein 1 and its ligand inhibitors in the treatment of late stage HCC].
    Xiao ZL; Wang P; Lei LP; Zhou HB; Hu HP
    Zhonghua Gan Zang Bing Za Zhi; 2019 Sep; 27(9):732-736. PubMed ID: 31594104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Immunotherapy for Hepatocellular Carcinoma.
    Nakano S; Eso Y; Okada H; Takai A; Takahashi K; Seno H
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of NK-based immunotherapy and sorafenib against hepatocellular carcinoma.
    Yang J; Eresen A; Scotti A; Cai K; Zhang Z
    Am J Cancer Res; 2021; 11(2):337-349. PubMed ID: 33575075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in immunotherapy for hepatocellular carcinoma.
    Khan AA; Liu ZK; Xu X
    Hepatobiliary Pancreat Dis Int; 2021 Dec; 20(6):511-520. PubMed ID: 34344612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.
    Donne R; Lujambio A
    Hepatology; 2023 May; 77(5):1773-1796. PubMed ID: 35989535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice.
    Giannini EG; Aglitti A; Borzio M; Gambato M; Guarino M; Iavarone M; Lai Q; Levi Sandri GB; Melandro F; Morisco F; Ponziani FR; Rendina M; Russo FP; Sacco R; Viganò M; Vitale A; Trevisani F;
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31671581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments with immunotherapy for hepatocellular carcinoma.
    Waidmann O
    Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.